The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Open accessAbstract
Purpose: Combining tumor antigens with an immunostimulant can induce the immune system to specifically eliminate cancer cells. Generally, this combination is accomplished in an ex vivo, customized manner. In a preclinical lymphoma model, intratumoral injection of a Toll-like receptor 9 (TLR9) agonist induced systemic antitumor immunity and cured large, disseminated tumors. Patients and Methods: We treated 15 patients with low-grade B-cell lymphoma using low-dose radiotherapy to a single tumor site and—at that same site—injected the C-G enriched, synthetic oligodeoxynucleotide (also referred to as CpG) TLR9 agonist PF-3512676. Clinical responses were assessed at distant, untreated tumor sites. Immune responses were evaluated by measuring T-cell activation after in vitro restimulation with autologous tumor cells. Results: This in situ vaccination maneuver was well-tolerated with only grade 1 to 2 local or systemic reactions and no treatment-limiting adverse events. One patient had a complete clinical response, three others had partial responses, and two patients had stable but continually regressing disease for periods significantly longer than that achieved with prior therapies. Vaccination induced tumor-reactive memory CD8 T cells. Some patients' tumors were able to induce a suppressive, regulatory phenotype in autologous T cells in vitro; these patients tended to have a shorter time to disease progression. One clinically responding patient received a second course of vaccination after relapse resulting in a second, more rapid clinical response. Conclusion: In situ tumor vaccination with a TLR9 agonist induces systemic antilymphoma clinical responses. This maneuver is clinically feasible and does not require the production of a customized vaccine product.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Higano, C. S., Schellhammer, P. F., Small, E. J., Burch, P. A., Nemunaitis, J., Yuh, L., Provost, N., & Frohlich, M. W. (2009) · Cancer · doi:10.1002/cncr.24429 · Cited by 810
Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591
Timmerman, J. M., Czerwinski, D. K., Davis, T. A., Hsu, F. J., Benike, C., Hao, Z. M., Taidi, B., Rajapaksa, R., Caspar, C. B., Okada, C. Y., et al. (2002) · Blood · doi:10.1182/blood.v99.5.1517 · Cited by 545
Self-citationKwak, L. W., Campbell, M. J., Czerwinski, D. K., Hart, S., Miller, R. A., & Levy, R. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210223271705 · Cited by 533
Self-citationCarreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E., Campo, E., & Banham, A. H. (2006) · Blood · doi:10.1182/blood-2006-04-018218 · Cited by 503
Yang, Z.-Z., Novak, A. J., Stenson, M. J., Witzig, T. E., & Ansell, S. M. (2006) · Blood · doi:10.1182/blood-2005-08-3376 · Cited by 420
Tzankov, A., Meier, C., Hirschmann, P., Went, P., Pileri, S. A., & Dirnhofer, S. (2008) · Haematologica · doi:10.3324/haematol.11702 · Cited by 412
Bourke, E., Bosisio, D., Golay, J., Polentarutti, N., & Mantovani, A. (2003) · Blood · doi:10.1182/blood-2002-11-3355 · Cited by 384
Deng, Y., Jing, Y., Campbell, A. E., & Gravenstein, S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.6.3437 · Cited by 230
Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Ribas, A., Comin-Anduix, B., Chmielowski, B., Jalil, J., de la Rocha, P., McCannel, T. A., Ochoa, M. T., Seja, E., Villanueva, A., Oseguera, D. K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1254 · Cited by 217
Decker, T., Schneller, F., Sparwasser, T., Tretter, T., Lipford, G. B., Wagner, H., & Peschel, C. (2000) · Blood · doi:10.1182/blood.v95.3.999.003k10_999_1006 · Cited by 210
Krieg, A. M., Efler, S. M., Wittpoth, M., Al Adhami, M. J., & Davis, H. L. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00006 · Cited by 184
Haas, R. L. M., Poortmans, P., de Jong, D., Aleman, B. M. P., Dewit, L. G. H., Verheij, M., Hart, A. A. M., van Oers, M. H. J., van der Hulst, M., Baars, J. W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.542 · Cited by 175
Link, B. K., Ballas, Z. K., Weisdorf, D. J., Wooldridge, J. E., Bossler, A., Shannon, M., Rasmussen, W. L., Krieg, A. Μ., & Weiner, G. J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211304.60126.8f · Cited by 153
Hofmann, M. A., Kors, C., Audring, H., Walden, P., Sterry, W., & Trefzer, U. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318174a4df · Cited by 153
Clinical Benefit Associated With Idiotypic Vaccination in Patients With Follicular Lymphoma
Inogés, S., Rodrı́guez-Calvillo, M., Zabalegui, N., de Cerio, A. L.-D., Villanueva, H., Soria, E., Suárez, L., Rodríguez‐Caballero, A., Pastor, F., García‐Muñoz, R., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj358 · Cited by 150
Freedman, A. S., Neelapu, S. S., Nichols, C. R., Robertson, M. J., Djulbegović, B., Winter, J. N., Bender, J. F., Gold, D. P., Ghalie, R., Stewart, M. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8903 · Cited by 138
Li, J., Song, W., Czerwinski, D. K., Varghese, B., Uematsu, S., Akira, S., Krieg, A. Μ., & Levy, R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2493 · Cited by 125
Self-citationMolenkamp, B. G., Sluijter, B. J. R., van Leeuwen, P. A. M., Santegoets, S. J. A. M., Meijer, S., Wijnands, P. G. J. T. B., Haanen, J. B. A. G., van den Eertwegh, A. J. M., Scheper, R. J., & de Gruijl, T. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4711 · Cited by 125
Nicola, M. D., Zappasodi, R., Carlo‐Stella, C., Mortarini, R., Pupa, S. M., Magni, M., Devizzi, L. F., Matteucci, P., Baldassari, P., Ravagnani, F., et al. (2008) · Blood · doi:10.1182/blood-2008-06-165654 · Cited by 122
B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides
Jahrsdörfer, B., Mühlenhoff, L., Blackwell, S. E., Wagner, M., Poeck, H., Hartmann, E., Jox, R. J., Giese, T., Emmerich, B., Endres, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1890 · Cited by 121
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma
Neelapu, S. S., Kwak, L. W., Kobrin, C. B., Reynolds, C. W., Janik, J. E., Dunleavy, K. M., White, T., Harvey, L. K., Pennington, R., Stetler‐Stevenson, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1290 · Cited by 111
Leonard, J. P., Link, B. K., Emmanouilides, C. E., Gregory, S. A., Weisdorf, D. J., Andrey, J., Hainsworth, J. D., Sparano, J. A., Tsai, D. E., Horning, S. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0815 · Cited by 108
Successful combination of local CpG‐ODN and radiotherapy in malignant glioma
Meng, Y., Carpentier, A. F., Chen, L., Boisserie, G., Simon, J.-M., Mazeron, J., & Delattre, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.21131 · Cited by 105
Sosman, J. A., Carrillo, C., Urba, W. J., Flaherty, L. E., Atkins, M. B., Clark, J. I., Dutcher, J., Margolin, K. A., Mier, J. W., Gollob, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3165 · Cited by 104
Redfern, C. H., Guthrie, T. H., Bessudo, A., Densmore, J. J., Holman, P., Janakiraman, N., Leonard, J. P., Levy, R. L., Just, R. G., Smith, M. R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4289 · Cited by 90
Self-citationSchuster, S. J., Neelapu, S. S., Gause, B. L., Muggia, F. M., Gockerman, J. P., Sotomayor, E. M., Winter, J. N., Flowers, C. R., Stergiou, A. M., & Kwak, L. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2 · Cited by 85
Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T‐regulatory cells
Ai, W. Z., Hou, J., Zeiser, R., Czerwinski, D. K., Negrin, R. S., & Levy, R. (2008) · International Journal of Cancer · doi:10.1002/ijc.23881 · Cited by 75
Self-citationThe clinical course of follicular lymphoma
Rohatiner, A. Z. S., & Lister, T. A. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.06.002 · Cited by 55
Schuster, S. J., Neelapu, S. S., Gause, B. L., Muggia, F. M., Gockerman, J. P., Sotomayor, E. M., Winter, J. N., Flowers, C. R., Stergiou, A. M., & Kwak, L. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.2 · Cited by 39
Brody, J., Goldstein, M. J., Czerwinski, D. K., & Levy, R. (2008) · Blood · doi:10.1182/blood-2008-05-155457 · Cited by 37
Self-citationTopical CpG Enhances the Response of Murine Malignant Melanoma to Dacarbazine
Najar, H. M., & Dutz, J. P. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.59 · Cited by 29
Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
Fournier, P., & Schirrmacher, V. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.8.1.51 · Cited by 25
Treanor, J. J., Wu, H., Liang, H., & Topham, D. J. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.006 · Cited by 16
Cited by
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Metadata
- Authors
- Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., Wapnir, I., Tibshirani, R. J., & Levy, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-10-01
- Volume
- 28
- Issue
- 28
- Pages
- 4324-4332
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2170612601
- Cited by
- 487
- References
- 36
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.